Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Summary

The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy. Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications